Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Continues To Shed Pipeline Assets In Roivant Deal

This article was originally published in PharmAsia News

Executive Summary

Takeda has set up a new company with Roivant to expedite the development of relugolix, an oral GnRH antagonist, for indications including prostate cancer and endometriosis.

Advertisement

Related Content

Takeda Paves The Way For Myovant With Phase III Fibroid Success
Myovant On Path To Women’s Health Leadership, CEO Says
Myovant CEO Says Buoyant IPO Reflects High Interest In Women's Health
Start-Up Quarterly Statistics, Q2 2016

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC089615

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel